The stock price of Kezar Life Sciences Inc (NASDAQ: KZR) has jumped by 9.14 compared to previous close of 7.50. Despite this, the company has seen a gain of 1.99% in its stock price over the last five trading days. businesswire.com reported 2024-10-28 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the “Effective Time”). The Co.
Is It Worth Investing in Kezar Life Sciences Inc (NASDAQ: KZR) Right Now?
KZR has 36-month beta value of 0.21. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KZR is 6.21M, and currently, short sellers hold a 1.92% ratio of that float. The average trading volume of KZR on October 31, 2024 was 85.13K shares.
KZR’s Market Performance
KZR’s stock has seen a 1.99% increase for the week, with a 3.57% rise in the past month and a 29.18% gain in the past quarter. The volatility ratio for the week is 9.17%, and the volatility levels for the past 30 days are at 6.96% for Kezar Life Sciences Inc The simple moving average for the past 20 days is 0.60% for KZR’s stock, with a 8.58% simple moving average for the past 200 days.
Analysts’ Opinion of KZR
Many brokerage firms have already submitted their reports for KZR stocks, with Wells Fargo repeating the rating for KZR by listing it as a “Equal Weight.” The predicted price for KZR in the upcoming period, according to Wells Fargo is $4 based on the research report published on August 11, 2023 of the previous year 2023.
Wells Fargo gave a rating of “Overweight” to KZR, setting the target price at $19 in the report published on December 08th of the previous year.
KZR Trading at 18.97% from the 50-Day Moving Average
After a stumble in the market that brought KZR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.84% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 9.17%, as shares sank -1.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.39% upper at present.
During the last 5 trading sessions, KZR rose by +1.99%, which changed the moving average for the period of 200-days by -7.98% in comparison to the 20-day moving average, which settled at $8.1400. In addition, Kezar Life Sciences Inc saw -13.55% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KZR starting from Schiller Mark C., who sale 6,688 shares at the price of $0.58 back on Jul 02 ’24. After this action, Schiller Mark C. now owns 33,007 shares of Kezar Life Sciences Inc, valued at $3,879 using the latest closing price.
Stock Fundamentals for KZR
Current profitability levels for the company are sitting at:
- -63.32 for the present operating margin
- 0.31 for the gross margin
The net margin for Kezar Life Sciences Inc stands at -62.7. The total capital return value is set at -0.61. Equity return is now at value -51.48, with -44.47 for asset returns.
Based on Kezar Life Sciences Inc (KZR), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -5.88. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -123.81.
Currently, EBITDA for the company is -104.17 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 373.34. The receivables turnover for the company is 0.93for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.58.
Conclusion
To put it simply, Kezar Life Sciences Inc (KZR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
